medicaid approved glp 1 covers GLP-1 meds for obesity in just 13 states, analysis finds Does Medicaid Cover Ozempic &

Management of inflammation in cardiovascular diseases

Food and Drug Administration (FDA) approved a new indication for semaglutide to reduce cardiovascular risk in adults with established cardiovascular disease (CVD) and overweight or obesity

As the arsenal of incretin therapies targeting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors continues to expand, clinicians need to balance the myriad clinical benefits with potentially severe adverse effects (AEs) to put this principle into practice

Real-world data reveals that adherence rates for GLP-1 therapies are significantly lower than for Metformin, largely due to side effects both medications can cause